| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2018-10-10 | Secarna Pharmaceuticals (Germany) | grant | European Commission’s Horizon 2020 programme | Rare diseases - Fibrotic diseases - Lung diseases | Grant | |
| 2018-10-10 | Allogene Therapeutics (USA - CA) | $324.0 million | IPO | Cancer - Oncology | IPO | |
| 2018-10-10 | Allogene Therapeutics (USA - CA) | $324 million | IPO | Cancer - Oncology | IPO | |
| 2018-10-10 | Histogenics (USA - MA) | $15.4 million | private placement | Regenerative Medicine - Bone diseases | Private placement | |
| 2018-10-10 | RoslinCT (UK) Reprocell (UK) | £1.2 million | grant | Innovate UK (UK) | Technology - Services | Grant |
| 2018-10-05 | Epizyme (USA - MA) | $86.25 million | private placement | Cancer - Oncology - Rare diseases | Private placement | |
| 2018-10-05 | Alligator Bioscience (Sweden) | 500 000 SEK (€ 47 845) | grant | Vinnova, Swedish Governmental Agency for Innovation Systems (Sweden) | Cancer - Oncology | Grant |
| 2018-09-26 | Minoryx Therapeutics (Spain) | €21.3 million | series B financing round | Chiesi Ventures (Italy) Caixa Capital Risc (Spain) HealthEquity (Spain) Fund+ (Belgium) Idinvest Partners (France) Kurma Partners (France) Sambrinvest (Belgium) Kurma Partners (France) Ysios Capital (Spain) SFPI-FPIM, S.R.I.W | Rare diseases | Series B financing round |
| 2018-09-20 | Fate Therapeutics (USA - CA) | private placement | Cancer - Oncology - Immunological diseases | Private placement | ||
| 2018-09-20 | Y-mAbs Therapeutics (USA - NY) | IPO | Cancer - Oncology | IPO | ||
| 2018-09-12 | CODA Biotherapeutics (USA - CA) | $19 million | series A financing round | MPM Capital (USA - MA) Versant Ventures (USA - CA) Astellas Venture Management (USA - CA) Novartis (Switzerland) | Neurological diseases - CNS diseases | Series A financing round |
| 2018-09-12 | Exocobio (Republic of Korea) | $27 million | series B financing round | Seven Tree Equity Partners (Republic of Korea) CSQUARED Global Asset Management (Republic of Korea) TS Investment Partners (Dubai) K2 Investment, Intervest (Republic of Korea) KDB Capital (Republic of Korea) Atinum Investment (Republic of Korea) GU Equity Partners (Republic of Korea) QUANTUM Ventures Korea (Republic of Korea) Platinum technology Investment (Republic of Korea) | Autoimmune diseases - Dermatological diseases | Series B financing round |
| 2018-09-07 | Oasmia Pharmaceutical (Sweden) | SEK 35.2 million | private placement | Cancer - Oncology | Private placement | |
| 2018-09-06 | Twentyeight-Seven Therapeutics (USA - MA) | $65 million | series A financing round | MPM Capital (USA - MA) Novartis Venture Fund (USA - MA) Johnson & Johnson Innovation – JJDC (USA - NJ) Vertex Ventures (USA - CA) Longwood Fund (USA - MA) Astellas Venture Management (USA - CA) | Cancer - Oncology | Series A financing round |
| 2018-09-06 | Allogene Therapeutics (USA - CA) | $120 Million | financing round | Cancer - Oncology | Financing round | |
| 2018-09-05 | Retrophin (USA - CA) | $240 million | private placement | Rare diseases | Private placement | |
| 2018-08-31 | Antabio (France) | € 12.5 million | series A financing round | iXO Private Equity (France) IRDI SORIDEC Gestion (France) Galia Gestion (France) Omnes Capital (France) BNP Paribas Développement (France) Sham Innovation Santé (Turenne Capital) (France) and company’s historical investors including former President of OM Pharma Christophe Ricard. | Rare diseases - Infectious diseases | Series A financing round |
| 2018-08-13 | Orchard Therapeutics (UK) | $150 Million | series C financing round | ArrowMark Partners (USA - CO) Cormorant Asset Management (USA - MA) Foresite Capital (USA - NY) RA Capital Management (USA - MA) Perceptive Advisors (USA - NY) RTW Investments (USA - NY) Venrock (USA - CA) Foresite Capital (USA - NY) Sphera Global Healthcare (Spain) Medison Ventures Driehaus Capital Management (USA - IL) Ghost Tree Capital Group (USA - NY) Temasek (Singpore) Baillie Gifford (UK) Cowen Healthcare (USA - NY) Agent Capital (USA - MA) | Rare diseases - Genetic diseases | Series C financing round |
| 2018-08-08 | Beigene (China) | $903 million | IPO | Cancer - Oncology | IPO | |
| 2018-08-06 | Pharmaxis (Australia) | A$24 million (£13.4 million - €15.35 million) | financing round | Arix Bioscience (UK) BVF Partners (USA - CA) other existing shareholders | Fibrotic diseases - Inflammatory diseases | Financing round |
